HU9600587D0 - Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains - Google Patents

Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains

Info

Publication number
HU9600587D0
HU9600587D0 HU9600587A HU9600587A HU9600587D0 HU 9600587 D0 HU9600587 D0 HU 9600587D0 HU 9600587 A HU9600587 A HU 9600587A HU 9600587 A HU9600587 A HU 9600587A HU 9600587 D0 HU9600587 D0 HU 9600587D0
Authority
HU
Hungary
Prior art keywords
peptides
hiv
nucleotide sequences
sequences
fusion
Prior art date
Application number
HU9600587A
Other languages
English (en)
Other versions
HU219507B (hu
HUT76102A (en
Inventor
Hermann Katinger
Thomas Muster
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Publication of HU9600587D0 publication Critical patent/HU9600587D0/hu
Publication of HUT76102A publication Critical patent/HUT76102A/hu
Publication of HU219507B publication Critical patent/HU219507B/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9600587A 1993-09-11 1994-09-12 Genetikailag divergens HIV-1-törzsekkel szemben neutralizáló ellenanyagok termelődését kiváltó peptidek HU219507B (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93114631 1993-09-11
PCT/EP1994/003039 WO1995007354A1 (en) 1993-09-11 1994-09-12 Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains

Publications (3)

Publication Number Publication Date
HU9600587D0 true HU9600587D0 (en) 1996-05-28
HUT76102A HUT76102A (en) 1997-06-30
HU219507B HU219507B (hu) 2001-04-28

Family

ID=8213253

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9600587A HU219507B (hu) 1993-09-11 1994-09-12 Genetikailag divergens HIV-1-törzsekkel szemben neutralizáló ellenanyagok termelődését kiváltó peptidek

Country Status (15)

Country Link
EP (1) EP0725825B1 (hu)
JP (1) JPH09502348A (hu)
CN (1) CN1135237A (hu)
AT (1) ATE199260T1 (hu)
AU (1) AU682893B2 (hu)
BR (1) BR9407531A (hu)
CA (1) CA2171544C (hu)
CZ (1) CZ287808B6 (hu)
DE (1) DE69426725T2 (hu)
ES (1) ES2156902T3 (hu)
HU (1) HU219507B (hu)
PT (1) PT725825E (hu)
RU (1) RU2181379C2 (hu)
UA (1) UA43350C2 (hu)
WO (1) WO1995007354A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2178672T3 (es) * 1995-04-19 2003-01-01 Polymun Scient Immunbio Forsch Anticuerpos monoclonales frente al vih-1 y vacunas hechas a partir de ellos.
US6319890B1 (en) 1996-12-30 2001-11-20 Manfred P. Dierich Inhibition of binding of complement Factor H
DE69926061T2 (de) * 1998-03-23 2006-06-01 Trimeris Inc. Verfahren und zusammensetzungen zur peptidsynthese (t-20)
US6482928B1 (en) 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1754715A1 (de) 2005-08-19 2007-02-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Impfstoff auf Basis virusneutralisierender Antikörper
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2750067C (en) * 2009-02-06 2018-08-21 Mymetics Corporation Splitting gp41
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053413T3 (es) * 1992-05-14 1997-11-16 Polymun Scient Immunbio Forsch Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Also Published As

Publication number Publication date
UA43350C2 (uk) 2001-12-17
AU7696594A (en) 1995-03-27
AU682893B2 (en) 1997-10-23
WO1995007354A1 (en) 1995-03-16
CZ74196A3 (en) 1996-07-17
ATE199260T1 (de) 2001-03-15
EP0725825B1 (en) 2001-02-21
JPH09502348A (ja) 1997-03-11
EP0725825A1 (en) 1996-08-14
CA2171544C (en) 2003-06-24
CZ287808B6 (en) 2001-02-14
PT725825E (pt) 2001-08-30
RU2181379C2 (ru) 2002-04-20
DE69426725D1 (de) 2001-03-29
HU219507B (hu) 2001-04-28
ES2156902T3 (es) 2001-08-01
DE69426725T2 (de) 2001-09-06
CN1135237A (zh) 1996-11-06
BR9407531A (pt) 1997-08-26
CA2171544A1 (en) 1995-03-16
HUT76102A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
DE3588251T2 (de) DNS-Fragmente des GAG-Gens von LAV
CA2392877A1 (en) Improvements in or relating to immune responses to hiv
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
HU9600587D0 (en) Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains
US20040180329A1 (en) Synthetic HIV gag genes
WO1998034640A2 (en) Synthetic hiv gag genes
CA2107732A1 (en) Retrovirus from the hiv group and its use
CA2143163A1 (en) Peptides derived from a retrovirus of the hiv group, and their use
BRAND et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
JP2004509601A5 (hu)
WARNER et al. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells
US7670610B2 (en) Recombinant BCG vaccine
Le Blanc et al. HTLV-1 structural proteins
WO1993018055B1 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
CA2169603A1 (en) Retrovirus from the hiv group and its use
CA2084386A1 (en) Hiv antigen
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
Lockey et al. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees
JPH05508324A (ja) ハイブリッド形態の新規可溶性、非開裂性gp160変異体
EP0950063B1 (en) Multiple branch peptide constructions
EP0469089A1 (en) Generation of hybrid genes and proteins by virus-mediated recombination
Vogt et al. Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins
FR2607518A1 (fr) Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus
Girard et al. Candidate vaccines for HIV
Haynes et al. Strategy for developing a genetically-engineered whole-virus vaccine against HIV

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee